Company intelligence / Profile preview

Cholrem

Clear Island Waters, Queensland, Australia

Ownership: Private
Development stage: Other

Overview

Published case series of 20 high-risk patients with advanced angina showed 90% reported substantial symptom improvement with objective imaging recording Coronary Artery Calcium score reductions and reduction of 70% coronary artery blockage to 27%

Therapeutic areas: NephrologyCardiovascularNeurologyOphthalmology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

hydroxypropyl betadex

Preclinical

Beyond the preview

Go deeper on Cholrem.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cholrem.

Explore the full profile